# A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Source: https://onco.cc/trials/nct06760819/  
OnCo record `nct06760819` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BAY2927088 in advanced solid tumours, run by Bayer, now recruiting.

## Summary

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) is a phase 2 interventional study registered as NCT06760819 by Bayer, with 111 participants planned, started 2025-02-13 and due to reach its primary completion in 2029-02-02. Interventions recorded: BAY2927088.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06760819
- Phase: 2
- Setting: A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
- Sponsor: Bayer
- Enrolled: 111

## Sources

- ClinicalTrials.gov NCT06760819: https://clinicaltrials.gov/study/NCT06760819

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct06760819.json